AWM
SPRO icon

Axxcess Wealth Management’s Spero Therapeutics SPRO Stock Holding History

Axxcess Wealth Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.9K Buy
+32,548
New +$85.1K ﹤0.01% 1043
2026
Q1 		– Sell
-32,548
Closed -$75.8K – 916
2025
Q4 		$75.8K Hold
32,548
– – ﹤0.01% 1025
2025
Q3 		$61.2K Hold
32,548
– – ﹤0.01% 921
2025
Q2 		$94.4K Buy
+32,548
New +$46.8K ﹤0.01% 868

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Axxcess Wealth Management's SPRO Position: Q2 2026 in Review

Axxcess Wealth Management opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 32,548 shares worth $71.9K. The stake represents ﹤0.01% of the portfolio and ranks #1043 among its holdings. This is a return to the name: Axxcess Wealth Management previously reported a position in SPRO as recently as Q4 2025.

Axxcess Wealth Management first reported a position in SPRO in Q2 2025 and has held it in 4 quarters since. The position peaked at $94.4K in Q2 2025. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Axxcess Wealth Management held 32,548 shares of Spero Therapeutics worth $71.9K as of Q2 2026.
  • Spero Therapeutics was a new Axxcess Wealth Management position in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of Axxcess Wealth Management's portfolio in Q2 2026, its #1043 holding.
  • Axxcess Wealth Management first reported a position in Spero Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Axxcess Wealth Management's Spero Therapeutics position peaked at $94.4K in Q2 2025.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Axxcess Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.